Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Niagen Bioscience, Inc. (NAGE) had Consolidated Net Income/Loss of $6.32M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$31.47M |
|
$6.32M |
|
$11.50M |
|
$19.98M |
|
$29.90M |
|
$1.58M |
|
$5.16M |
|
$6.74M |
|
$6.74M |
|
$6.32M |
|
$6.32M |
|
|
Consolidated Net Income/Loss |
$6.32M |
$6.32M |
|
$1.58M |
|
$1.87M |
|
79.92M |
|
84.57M |
|
$0.08 |
|
$0.07 |
|
| Balance Sheet Financials | |
$105.12M |
|
$1.30M |
|
$9.21M |
|
$114.33M |
|
$22.82M |
|
-- |
|
$9.18M |
|
$32.00M |
|
$82.33M |
|
$76.84M |
|
$82.33M |
|
79.46M |
|
| Cash Flow Statement Financials | |
$-1.19M |
|
$5.25M |
|
$-2.29M |
|
$64.79M |
|
$66.55M |
|
$1.76M |
|
$1.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.61 |
|
-- |
|
-- |
|
-- |
|
-- |
|
63.47% |
|
5.01% |
|
5.01% |
|
-- |
|
21.40% |
|
20.07% |
|
$4.54M |
|
-- |
|
-- |
|
-- |
|
0.28 |
|
0.48 |
|
2.41 |
|
37.37 |
|
7.67% |
|
8.22% |
|
5.53% |
|
7.67% |
|
$1.04 |
|
$0.05 |
|
$-0.01 |
|